CLEARWATER, Fla.--(BUSINESS WIRE)--Bovie Medical (NYSE MKT:BVX), a maker of medical devices and supplies and the developer of J-Plasma®, a patented new surgical product, provided an update on operating developments.
The Company is pleased to announce that the first two white papers on J-Plasma® will be published on July 1, 2014 and made available simultaneously on Bovie Medical’s website. The first paper tracks J-Plasma’s® effect on tissue compared to the effects of cautery, argon and monopolar lasers, and the other analyzes the versatility of the J-Plasma® product’s power settings. A third white paper that evaluates the pre- and post-procedural results on facial wrinkles is scheduled to be published in the third quarter.
“We continue to progress on or ahead of schedule with the commercialization of our J-Plasma® product,” said Robert L. Gershon, Chief Executive Officer. “Our surgeon pipeline is growing, and we held an additional surgeon training program in Las Vegas this month. In August, we will bring together our J-Plasma® direct salesforce and distributor network for 3-days of intense clinical and product training and certification.”
Bovie Medical is adding to its core equipment/device business through the launch of Derm 101 and 102, efficient and economical high frequency desiccators that provides a low wattage platform for minor in-office skin procedures. The product will be available for purchase in August.
The Company also announced today that it has hired Jay D. Ewers as Controller, effective June 23, 2014. Mr. Ewers comes to Bovie with more than 30 years of senior experience in all phases of finance, accounting, administrative and general management. He has held financial executive positions in the manufacturing, medical equipment, semiconductor and retail industries at companies ranging from early stage and high growth to high profile public companies. Mr. Ewers entered into an employment agreement with the Company and was awarded a non-qualified stock option to purchase an aggregate of 35,000 shares of Bovie common stock, exercisable at the closing price on the effective date of his employment agreement. The option shall vest and be exercisable in four equal annual installments beginning on the first anniversary of the effective date.
“Jay’s appointment is another illustration of our commitment to building the solid infrastructure required to support future growth, and it further demonstrates our ability to attract top-flight executives to the Company,” Mr. Gershon said.
About Bovie Medical Corporation
Bovie Medical Corporation is a leading maker of medical devices and supplies as well as the developer of J-Plasma®, a patented new plasma-based surgical product. J-Plasma® utilizes a gas ionization process that produces a stable, focused beam of ionized gas that provides surgeons with greater precision, minimal invasiveness and an absence of conductive currents through the patient during surgery. Bovie Medical Corporation is also a leader in the manufacture of a range of electrosurgical products and technologies, marketed through both private labels and the Company’s own well-respected brands (Bovie®, Aaron®, IDS™ and ICON™) to distributors worldwide. The Company also leverages its expertise through original equipment manufacturing (OEM) agreements with other medical device manufacturers. For further information about the Company’s current and new products, please refer to the Investor Relations section of Bovie Medical Corporation’s website www.boviemed.com.
Cautionary Statement on Forward-Looking Statements
Certain matters discussed in this release and oral statements made from time to time by representatives of the Company may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and the Federal securities laws. Although the Company believes that the expectations reflected in such forward-looking statements are based upon reasonable assumptions, it can give no assurance that its expectations will be achieved.
Forward-looking information is subject to certain risks, trends and uncertainties that could cause actual results to differ materially from those projected. Many of these factors are beyond the Company’s ability to control or predict. Important factors that may cause actual results to differ materially and that could impact the Company and the statements contained in this release can be found in the Company’s filings with the Securities and Exchange Commission including the Company’s reports on Forms 10-K/A and 10-Q for the year ended December 31, 2013 and the quarter ended March 31, 2014, respectively. For forward-looking statements in this release, the Company claims the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. The Company assumes no obligation to update or supplement any forward-looking statements whether as a result of new information, future events or otherwise.